CPC Of America Gains Access to Large Patient Population in Florida; Company Clarifies Benefits of MSO Agreement With Metropolitan Health Networks, Inc.

SARASOTA, Fla.--(BW HealthWire)--January 6, 1999--CPC OF AMERICA, INC. (OTC BB: CPCF) ("CPC") today clarified its recently announced Managed Services Organization ("MSO") agreement with Metropolitan Health Networks, Inc. (NASDQ: MDPA) ("Metropolitan") of Boca Raton, Florida.

On December 30, 1998, CPC and Metropolitan entered into a long-term agreement, under which, Metropolitan will provide exclusive MSO services to CPC, that will include company owned and co-source joint venture counter pulsation care facilities. The agreement also provides for the cross-marketing of each firm's products and services.

Rod Shipman, President and Chief Executive Officer of CPC of America, Inc., stated, "Our agreement with Metropolitan offers CPC significant opportunities. Metropolitan, through its agreement with Humana Inc. (NYSE: HUM), provides CPC with access to 900,000 of the estimated 1,400,000 Medicare lives in the State of Florida, giving Metropolitan and CPC a large base of potential patients with coronary artery disease. In addition, Metropolitan currently serves over one hundred cardiologists through its mobile ultrasound and imaging business. This will enable both Companies to expand each other's services in the treatment of coronary artery disease upon receipt of FDA clearance for CPC's, CPCA2000(TM), expected early this year."

Metropolitan Health Networks, Inc. is a multi-specialty group practice. The Company's fundamental strategy is to develop a dominant integrated group practice and network management company in the South Florida market, providing comprehensive medical treatment and ancillary services to its patients and Management Services to the physician community.

CPC of America, Inc. is a development stage company that intends to develop, acquire, manufacture and market state-of-the-art medical technology. The company developed the CPCA2000(TM) for the non-invasive treatment of patients with coronary artery disease, and has submitted an application for the CPCA2000(TM) to the FDA for marketing clearance on November 12, 1998. CPC has patents pending in the United States and other countries covering the system and its many features. In addition, CPCF intends to acquire joint venture and expand MSOs for the management of cardiology practices and enter into joint ventures to provide comprehensive cardiology services nationwide.

Statements in this news release may contain forward-looking information within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934, and is subject to the safe harbor created by those sections. All statements, other than statements of historical fact, included in this release including, without limitation, statements regarding potential future plans and objectives of CPC of America are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. CPC of America assumes no obligation to update information contained in this release. This news release contains forward-looking statements regarding the potential market for a new product, 510(k) submission, and the time frame in which new products are expected to contribute revenues, which are based upon current expectations, that involve a number of risks and uncertainties including, but no limited to, technological innovations of competitors, changes in health-care regulations, litigation claims, foreign currency fluctuations, product acceptance, or changes in government regulations of the Company's products, as well as other factors discussed in the Company's last report on Form 10-K-SB under "Risk Factors".